Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Exclusion Criteria

• •Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of Day 0.
• •Subjects with any clinically important abnormal physical finding at Screening.
• •Subjects who have taken any prescription or investigational oral retinoid medication (e.g., Accutane,® Soriatane®) within 6 months of Day 0 and subjects who did not tolerate their previous oral retinoid medication will be excluded regardless of the time of last exposure.
• •Subjects with a history of diabetes or chronic hyperlipidemia, hepatitis, pancreatitis, or cirrhosis.
• •Subjects who have taken any supplements containing ≥10,000 IU vitamin A within 60 days of screening